ETERNAL
Financiado
Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle.
ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmenta...
ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only the API and residues/metabolites, but other chemicals and by-products of the production process. This type of approach is essential to take into consideration the types of green manufacturing approach under consideration by the pharmaceutical industry, as evidenced by the range and scope of case studies being undertaken within ETERNAL. Specific application of our risk and life cycle assessment approaches to the ETERNAL case studies is a key element of the proposed work and will provide industry and policymakers with key examples of how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction of green manufacturing processes.
ver más
Duración del proyecto: 51 meses
Fecha Inicio: 2022-05-23
Fecha Fin: 2026-08-31
Fecha Fin: 2026-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-23
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
AIMPLAS-ASOCIACIÓN DE INVESTIGACIÓN DE MATERI...
No se ha especificado una descripción o un objeto social para esta compañía.
423.31K€ |
Participante
N.D. |
Participante
1.09M€ |
Participante
303.13K€ |
Participante